Overview
Petitioner, Celltrion, Inc., filed IPRs challenging each claim
of U.S. Patent No. 8,580,264 ("the '264 patent") and
U.S. Patent No. 10,874,677 ("the '677 patent") as
anticipated under 35 U.S.C. § 102 and obvious under 35 U.S.C.
§ 103. IPR2022-00578, Paper 78 at *6, IPR2002-00579, Paper 72
at *5.
The Patent Trial and Appeal Board ("the Board") found
all claims of the challenged patents covering methods and devices
for treating rheumatoid arthritis unpatentable.
The '264 Patent
Background
The '264 patent is directed to a method of treating
rheumatoid arthritis (RA) with an anti-IL-6 receptor (IL-6R)
antibody. IPR2022-00578, Paper 78 at *4. Claims 1, 10, and 12 are
independent. Claims 1 and 10 recite, in relevant part: